YM-101

YM-101 is an investigational ophthalmic solution developed by the Eye & ENT Hospital of Fudan University for the treatment of dry eye syndrome. It is currently being evaluated in Phase 1 clinical trials to assess its safety and effectiveness in adult patients. The drug is administered as eye drops, typically twice daily, and has been studied in randomized, double-blind, placebo-controlled, cross-over trials. In these clinical settings, YM-101 is often administered alongside artificial tears to evaluate its therapeutic impact on ocular surface health and symptom relief. The specific molecular target and mechanism of action for YM-101 have not been publicly disclosed in the primary clinical trial documentation.